PharmaCyte Biotech, Inc. Quarterly Common Stock, Shares, Issued from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
PharmaCyte Biotech, Inc. quarterly Common Stock, Shares, Issued history and growth rate from Q1 2011 to Q2 2024.
  • PharmaCyte Biotech, Inc. Common Stock, Shares, Issued for the quarter ending July 31, 2024 was 21.7M shares, unchanged year-over-year.
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 21.7M 0 0% Jul 31, 2024 10-Q 2024-09-17
Q1 2024 21.7M +70K +0.32% Apr 30, 2024 10-Q 2024-09-17
Q4 2023 21.7M +70K +0.32% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 21.7M +70K +0.32% Oct 31, 2023 10-Q 2023-12-15
Q2 2023 21.7M +70K +0.32% Jul 31, 2023 10-Q 2023-09-18
Q1 2023 21.6M +881K +4.25% Apr 30, 2023 10-K 2024-08-13
Q4 2022 21.6M +882K +4.26% Jan 31, 2023 10-Q 2023-03-16
Q3 2022 21.6M +886K +4.28% Oct 31, 2022 10-Q 2022-12-14
Q2 2022 21.6M +20M +1240% Jul 31, 2022 10-Q 2022-09-14
Q1 2022 20.7M +19.1M +1203% Apr 30, 2022 10-K 2023-07-31
Q4 2021 20.7M -2.32B -99.1% Jan 31, 2022 10-Q 2022-03-15
Q3 2021 20.7M -2.31B -99.1% Oct 31, 2021 10-Q 2021-12-14
Q2 2021 1.61M -1.87B -99.9% Jul 31, 2021 10-Q 2021-09-14
Q1 2021 1.59M +498K Apr 30, 2021 10-K 2022-07-28
Q4 2020 2.34B +913M +63.9% Jan 31, 2021 10-Q 2021-03-12
Q3 2020 2.33B +1B +75.3% Oct 31, 2020 10-Q 2020-12-11
Q2 2020 1.88B +617M +49% Jul 31, 2020 10-Q 2020-09-11
Q1 2020 1.09M* -1.18B Apr 30, 2020 10-K 2021-08-10
Q4 2019 1.43B +302M +26.8% Jan 31, 2020 10-Q 2020-03-13
Q3 2019 1.33B +250M +23.2% Oct 31, 2019 10-Q 2019-12-23
Q2 2019 1.26B +179M +16.6% Jul 31, 2019 10-Q 2019-09-13
Q1 2019 1.19B +173M +17% Apr 30, 2019 10-K 2020-08-13
Q4 2018 1.13B +147M +15% Jan 31, 2019 10-Q 2019-03-14
Q3 2018 1.08B +108M +11.1% Oct 31, 2018 10-Q 2018-12-14
Q2 2018 1.08B +106M +10.9% Jul 31, 2018 10-Q 2018-09-12
Q1 2018 1.01B +108M +11.9% Apr 30, 2018 10-K 2019-08-13
Q4 2017 980M +108M +12.4% Jan 31, 2018 10-Q 2018-03-19
Q3 2017 973M +124M +14.6% Oct 31, 2017 10-Q 2017-12-14
Q2 2017 973M +125M +14.7% Jul 31, 2017 10-Q 2017-09-13
Q1 2017 905M +124M +15.9% Apr 30, 2017 10-K 2018-07-20
Q4 2016 872M +101M +13.1% Jan 31, 2017 10-Q/A 2017-03-13
Q3 2016 849M +102M +13.6% Oct 31, 2016 10-Q 2016-12-02
Q2 2016 849M +106M +14.3% Jul 31, 2016 10-Q 2016-09-06
Q1 2016 781M +48.5M +6.62% Apr 30, 2016 10-K 2017-07-27
Q4 2015 771M +67.9M +9.65% Jan 31, 2016 10-Q 2016-03-08
Q3 2015 747M +51.3M +7.37% Oct 31, 2015 10-Q/A 2016-01-19
Q2 2015 743M +32.3M +4.54% Jul 31, 2015 10-Q/A 2016-01-19
Q1 2015 733M +42.1M +6.1% Apr 30, 2015 10-K 2016-07-29
Q4 2014 703M +100M +16.7% Jan 31, 2015 10-Q 2015-03-13
Q3 2014 696M +108M +18.3% Oct 31, 2014 10-Q 2014-12-15
Q2 2014 710M +173M +32.3% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 691M +209M +43.3% Apr 30, 2014 10-K/A 2016-01-19
Q4 2013 603M +145M +31.7% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 588M +144M +32.4% Oct 31, 2013 10-Q 2013-12-16
Q2 2013 537M +114M +26.8% Jul 31, 2013 10-Q 2013-09-16
Q1 2013 482M +65.8M +15.8% Apr 30, 2013 10-K 2014-08-04
Q4 2012 458M +83.5M +22.3% Jan 31, 2013 10-Q 2013-03-26
Q3 2012 445M +70.2M +18.7% Oct 31, 2012 10-Q 2012-12-26
Q2 2012 423M +50.1M +13.4% Jul 31, 2012 10-Q 2012-09-19
Q1 2012 416M +59.2M +16.6% Apr 30, 2012 10-K 2013-07-29
Q4 2011 374M Jan 31, 2012 10-Q 2012-03-21
Q3 2011 374M Oct 31, 2011 10-Q 2011-12-15
Q2 2011 373M Jul 31, 2011 10-Q/A 2011-09-20
Q1 2011 357M Apr 30, 2011 10-K 2012-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.